Fewer contenders means fewer constraints on expanding market share.On the frontier of some of biopharma's lucrative markets, one competitor's stumble can be a win for one of its rivals. And it looks like Johnson & Johnson (JNJ 0.38%) just hit a bump in the road that'll pave the way for Eli Lilly (LLY 0.33%) to be more dominant in one such market within neuroscience.Here's what happened, and why it's bullish for Lilly's stock.This growing market now has one less aspiring entrantAs expected, Johnson & Johnson ...

Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform learned earlier this morning that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against MangoRx claiming, that MangoRx improperly copied its weight-loss medicine, Zepbound and Mounjaro. MangoRx strongly refutes any and all ...

Deutsche Bank Research 7T2se3r0Ot6kwoPa Rating Buy North America United States Health Care Pharmaceuticals / Major Company Eli Lilly and Company Reuters Bloomberg Exchange Ticker LLY.N LLY US NYS LLY 3Q24 Preview - Tirzep's Potential Miss a Blip... We think LLY prints 3Q24 Revs of $11.8B, missing BBG cons. by ~$400M, with non-GAAP EPS of $1.40/sh also falling short by 3 pennies. Despite this 3Q24 miss, we believe LLY maintains its FY24 rev guide of $45.4-$46.6B, though FY24 non-GAAP EPS guide gets updated t ...

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in LLY over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Disclaim ...

Eli Lilly just secured a huge win, and it's not related to the weight loss industry.Pharmaceutical powerhouse Eli Lilly (LLY 0.09%) is having a terrific 2024. Shares have gained 58% so far this year, handily outperforming both the S&P 500 and Nasdaq Composite indexes.Much of the share price appreciation can be attributed to Lilly's success in the diabetes and obesity care markets thanks to its blockbuster glucagon-like peptide-1 (GLP-1) agonists, Mounjaro and Zepbound. Moreover, Lilly made headlines back in ...

The stock of Eli Lilly and Company (LLY) has declined 1.7% already this week, losing almost $14 billion of its market value. Earlier this month, the FDA removed Lilly's popular GLP-1 drug tirzepatide from its shortage list after confirming with Lilly that it can meet the present and future demand with its manufacturing expansion. Lilly markets tirzepatide as Mounjaro for type II diabetes and Zepbound for obesity. Due to increased demand, tirzepatide was added to the FDA's shortage list in 2022. In the Unite ...

These innovative drugmakers have potential catalysts ahead.Once a company's shares rise rapidly, investors might wonder if it's still worth investing in the stock. The answer is that it depends. Some companies' strong performances are short-lived. Others perform well because they have attractive businesses that can deliver outsized returns in the long run. Those in the second category are worth investing in even after an impressive run.Let's look at two examples: Eli Lilly (LLY 1.34%) and Sarepta Therapeuti ...

Eli Lilly is investing billions into new research and manufacturing capabilities.Over the last couple of years, pharmaceutical giant Eli Lilly (LLY 0.34%) has made a splash in the red-hot weight loss space. The company's path-breaking innovation in using glucagon-like peptide-1 (GLP-1) agonists, Mounjaro and Zepbound, are just two of the company's blockbuster drugs helping pave the way in diabetes and obesity care, respectively.Lilly's success in the weight loss realm isn't without hiccups, though.  The com ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.Eli Lilly (LLY -0.74%) is the most valuable healthcare stock in the world, with a market capitalization north of $800 billion. In the past 12 months, its shares have risen by more than 50%, and while its growth prospects look strong, investors may balk at paying a multiple of more than 100 times its trailing earnings.However, while Eli Lilly's valuation may look pricey, that shouldn't diss ...

INDIANAPOLIS, Oct. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2024 financial results on Oct. 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://invest ...